ENTA vs. XERS, MGNX, CTNM, INZY, NLTX, AQST, RANI, XBIT, CRMD, and VTYX
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Xeris Biopharma (XERS), MacroGenics (MGNX), Contineum Therapeutics (CTNM), Inozyme Pharma (INZY), Neoleukin Therapeutics (NLTX), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), XBiotech (XBIT), CorMedix (CRMD), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical preparations" industry.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
Enanta Pharmaceuticals received 170 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a net margin of -37.58% compared to Enanta Pharmaceuticals' net margin of -180.76%. Enanta Pharmaceuticals' return on equity of -64.85% beat Xeris Biopharma's return on equity.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for Xeris Biopharma. Enanta Pharmaceuticals' average media sentiment score of 0.01 beat Xeris Biopharma's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.
Enanta Pharmaceuticals presently has a consensus target price of $19.00, suggesting a potential upside of 56.64%. Xeris Biopharma has a consensus target price of $4.63, suggesting a potential upside of 133.59%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Xeris Biopharma beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
